Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label pediatric pharmacokinetic and safety study of Orladeyo in hereditary angioedema
MOH_2022-07-21_011921Phase 3Not yet recruiting
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Pharmacokinetic parameters of berotralstat. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2022-07-21_011921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-21_011921.